Table 1.
Design Features and Baseline Characteristics Participants
| N | Mean Age, y |
Men % | DM % | Previous Stroke/TIA % |
Main Inclusion | Primary Outcome | ASA Dose, mg/d |
CPD Dose, mg/d |
Average Follow-Up |
% Lost to Follow-Up |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Short-Term Trials (14 d–3 mo) | |||||||||||
| CPD and ASA after surgery in CAD6 2007–2009 | 249 | 59 | 83 | 40 | 5 | Elective CABG | Graft occlusion at 3 mo | 100 | 75 | 3 mo | 3.6 |
| ASA vs ASA and CPD in lower limb angioplasty7 2002–2003 | 132 | 66 | 77 | 12 | NR | Leg atherosclerosis undergoing revascularization | Platelet responsiveness to stimulation | 75 | 300 ×1 then 75 | 30 d | none |
| PROCLAIM8 2005–2006 | 181 | 56 | 43 | NR | NR | Metabolic syndrome | Inflammatory markers | 81 | 75 | 6 wk | none |
| COMMIT9 1999–2005 | 45 852 | 61 | 72 | NR | NR | Acute MI with ST changes | Death/reinfarction/stroke and death from any cause | 162 | 75 | 15 d | <1 |
| Long-Term Trials (>3 mo) | |||||||||||
| SPS31 2003–2012 | 3020 | 63 | 63 | 37 | NR | Recent lacunar stroke | Recurrent stroke | 325 | 75 | 3.5 y | NR |
| CHARISMA10 2002–2004 | 15 603 | 64 | 70 | 42 | 25 | CV disease or multiple risk factors | Stroke, MI, and vascular death | 75–162 | 75 | 2.3 y | <1 |
| CURE11 1998–2000 | 12 562 | 64 | 62 | 23 | 4 | Acute coronary syndrome | Stroke, MI, and vascular death | 75–325 | 300 ×1 then 75 | 9 mo | <1 |
| ACTIVE A12 2003–2008 | 7554 | 71 | 58 | 19 | 13 | AF+1 risk factor | Stroke, MI, and vascular death | 96%: 75–100 3.5 %>100 | 75 | 3.6 y | <1 |
| CASCADE13 2006–2009 | 113 | 67 | 89 | 29 | NR | CABG with saphenous vein | Graft hyperplasia at 1 y | 162 | 75 | 1 y | none |
| CREDO14 1999–2001 | 2116 | 62 | 71 | 26 | 7 | Elective PCI | All death, stroke, MI | 325×28 d; then 81–325 | 300 ×1 then 75 | 1 y | 4 |
| REAL-LATE/ZEST-LATE15 2007–2010 | 2701 | 62 | 70 | 26 | 4 | Drug-eluting stents for 12 mo | MI or death from cardiac causes | 100–200 | 75 | 1.6 y | <1 |
| CASPAR16 2004–2006 | 851 | 66 | 76 | 38 | NR | Bypass for PVD | Graft occlusion or revascularization, amputation or death | 75–100 | 75 | 1 y | 2 |
| All trials | 90 934 | 63 | 70 | ⋯ | ⋯ | ⋯ | 75 | ⋯ | ⋯ |
DM indicates diabetes mellitus; TIA, transient ischemic attack; ASA, aspirin; CPD, clopidogrel; CAD, coronary artery disease; CABG, coronary artery bypass graft; NR, not reported; MI, myocardial infarction; CV, cardiovascular; AF, atrial fibrillation; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease.